Posted by Michael Wonder on 05 Nov 2024
Update on FDA review of Vtama (tapinarof) cream, 1% for the treatment of atopic dermatitis in adults and children 2 years of age and older
5 November 2024 - Organon today announced that the US FDA extended by three months the target action date of its review of the supplemental new drug application for Vtama (tapinarof) cream, 1% as a treatment for atopic dermatitis in adults and children two years of age and older.
The new target date is 12 March 2025, revised from the original target action date of 12 December 2024.
